Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer clue: could a DNA glitch open door to new treatments?

NCT ID NCT07303218

First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 30 times

Summary

This study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab models. The study does not give any experimental treatment—it just observes and analyzes samples from 100 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dept. Medical Oncology

    Milan, MI, 20132, Italy

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If this study finds that HRD is common in this lung cancer type, it could point toward using PARP inhibitor drugs for these patients in the future.

What could go wrong

This is an observational study, not a treatment trial. It is small (100 people) and only at one hospital, so results may not apply to everyone.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.